Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

327 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
[Adverse reactions during biological therapy for psoriasis: results of a survey of the Spanish Psoriasis Group].
Sánchez-Regaña M, Dilmé E, Puig L, Bordas X, Carrascosa JM, Ferran M, Herranz P, García-Bustinduy M, López Estebaranz JL, Alsina M, Rodríguez MA, Ribera M, Fernández-López E, Moreno JC, Belinchón Romero I, Vidal D; Grupo Español de Psoriasis de la Academia Española. Sánchez-Regaña M, et al. Among authors: carrascosa jm. Actas Dermosifiliogr. 2010 Mar;101(2):156-63. Actas Dermosifiliogr. 2010. PMID: 20223158 Spanish.
Risk of serious adverse events associated with biologic and nonbiologic psoriasis systemic therapy: patients ineligible vs eligible for randomized controlled trials.
Garcia-Doval I, Carretero G, Vanaclocha F, Ferrandiz C, Daudén E, Sánchez-Carazo JL, Alsina M, Herrera-Ceballos E, Gómez-García FJ, Ferrán M, López-Estebaranz JL, Hernanz JM, Belinchón-Romero I, Vilar-Alejo J, Rivera R, Carrascosa JM, Carazo C. Garcia-Doval I, et al. Among authors: carrascosa jm. Arch Dermatol. 2012 Apr;148(4):463-70. doi: 10.1001/archdermatol.2011.2768. Arch Dermatol. 2012. PMID: 22508869
Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting.
Navarro R, Vilarrasa E, Herranz P, Puig L, Bordas X, Carrascosa JM, Taberner R, Ferrán M, García-Bustinduy M, Romero-Maté A, Pedragosa R, García-Diez A, Daudén E. Navarro R, et al. Among authors: carrascosa jm. Br J Dermatol. 2013 Mar;168(3):609-16. doi: 10.1111/bjd.12045. Br J Dermatol. 2013. PMID: 22985451
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry.
Carrascosa JM, Vilavella M, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, Herrera-Ceballos E, De la Cueva Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Peral F, Torrado R, Rivera R, Jiménez-Puya R, Mendiola MV, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. J Eur Acad Dermatol Venereol. 2014 Jul;28(7):907-14. doi: 10.1111/jdv.12208. Epub 2013 Jul 15. J Eur Acad Dermatol Venereol. 2014. PMID: 23848131
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
Carretero G, Ferrandiz C, Dauden E, Vanaclocha Sebastián F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina-Gibert M, López-Estebaranz JL, Ferrán M, Torrado R, Carrascosa JM, Carazo C, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Carretero G, et al. Among authors: carrascosa jm. J Eur Acad Dermatol Venereol. 2015 Jan;29(1):156-63. doi: 10.1111/jdv.12492. Epub 2014 Mar 31. J Eur Acad Dermatol Venereol. 2015. PMID: 24684267
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
Medina C, Carretero G, Ferrandiz C, Dauden E, Vanaclocha F, Gómez-García FJ, Herrera-Ceballos E, De la Cueva-Dobao P, Belinchón I, Sánchez-Carazo JL, Alsina M, López-Estebaranz JL, Ferrán M, Carrascosa JM, Torrado R, Argila D, Rivera R, Jiménez-Puya R, García-Doval I; BIOBADADERM Study Group. Medina C, et al. Among authors: carrascosa jm. J Eur Acad Dermatol Venereol. 2015 May;29(5):858-64. doi: 10.1111/jdv.12688. Epub 2014 Sep 3. J Eur Acad Dermatol Venereol. 2015. PMID: 25185962
Use of off-label doses is frequent in biologic therapy for moderate to severe psoriasis: A cross-sectional study in clinical practice.
Carrascosa JM, Garcia-Doval I, Pérez-Zafrilla B, Carretero G, Vanaclocha F, Daudén E, De la Cueva-Dobao P, Belinchón I, Alsina M, López-Estebaranz JL, Ferrán M, Torrado R, Rivera R, Carazo C, Barboza L, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. J Dermatolog Treat. 2015;26(6):502-6. doi: 10.3109/09546634.2015.1034070. Epub 2015 Apr 17. J Dermatolog Treat. 2015. PMID: 25886087
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.
Carrascosa JM, Rivera N, Garcia-Doval I, Carretero G, Vanaclocha F, Daudén E, Gómez-García FJ, De-la-Cueva-Dobao P, Herrera-Ceballos E, Belinchón I, Alsina M, Sánchez-Carazo JL, Ferrán M, Lopez-Estebaranz JL, Pérez-Zafrilla B, Llamas M, Rivera R, Ferrándiz C; BIOBADADERM Study Group. Carrascosa JM, et al. Actas Dermosifiliogr. 2015 Oct;106(8):638-43. doi: 10.1016/j.ad.2015.04.013. Epub 2015 Jun 30. Actas Dermosifiliogr. 2015. PMID: 26141003 Free article. English, Spanish.
327 results